The widespread acceptance among the oncology community at large of cytoreductive surgery and HIPEC as a potentially curative treatment for peritoneal metastases has paved the way for innovative new therapies that could benefit a larger proportion of patients. Much has been and continues to be published on this subject. This book provides comprehensive reviews on the various aspects of managing peritoneal metastases. The authors highlight essential practical issues that surgical oncologists encounter in their day-to-day practice, and try to before provide evidence based answers to address…mehr
The widespread acceptance among the oncology community at large of cytoreductive surgery and HIPEC as a potentially curative treatment for peritoneal metastases has paved the way for innovative new therapies that could benefit a larger proportion of patients. Much has been and continues to be published on this subject.
This book provides comprehensive reviews on the various aspects of managing peritoneal metastases. The authors highlight essential practical issues that surgical oncologists encounter in their day-to-day practice, and try to before provide evidence based answers to address them. All chapters were written and/or reviewed by leading experts in this field.
''Dr. Aditi Bhatt is a Surgical oncologist specializing in the management of peritoneal surface malignancies. She has done her surgical oncology training from the Gujarat Cancer Research Institute in Ahmedabad, India and has further pursued a fellowship in peritoneal surface malignancies at Institut Gustave Roussy, Paris, France. She has been pursuing peritoneal surface oncology as a speciality for seven years. She was associate editor with Dr. Paul H. Sugarbaker for the special issue of the Indian Journal of Surgical Oncology on peritoneal surface malignancies in 2016. Dr. Aditi is currently involved in developing a robust system for collection and publication of Indian data pertaining to the management of peritoneal metastases and conducting multi-institutional studies. Here specific areas of interest are pseudomyoma peritonei and other rare peritoneal tumors and ovarian cancer.'
Inhaltsangabe
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
